- Home
- ROOT vs SNDX Comparison
ROOT vs SNDX Comparison
Compare ROOT & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROOT
- SNDX
- Stock Information
- Founded
- ROOT 2015
- SNDX 2005
- Country
- ROOT United States
- SNDX United States
- Employees
- ROOT N/A
- SNDX N/A
- Industry
- ROOT Property-Casualty Insurers
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- ROOT Finance
- SNDX Health Care
- Exchange
- ROOT Nasdaq
- SNDX Nasdaq
- Market Cap
- ROOT 2.3B
- SNDX 1.1B
- IPO Year
- ROOT 2020
- SNDX 2016
- Fundamental
- Price
- ROOT $100.21
- SNDX $15.04
- Analyst Decision
- ROOT Buy
- SNDX Strong Buy
- Analyst Count
- ROOT 6
- SNDX 10
- Target Price
- ROOT $130.60
- SNDX $38.40
- AVG Volume (30 Days)
- ROOT 439.3K
- SNDX 2.0M
- Earning Date
- ROOT 10-29-2025
- SNDX 11-04-2025
- Dividend Yield
- ROOT N/A
- SNDX N/A
- EPS Growth
- ROOT N/A
- SNDX N/A
- EPS
- ROOT 4.73
- SNDX N/A
- Revenue
- ROOT $1,364,700,000.00
- SNDX $77,933,000.00
- Revenue This Year
- ROOT $27.41
- SNDX $585.73
- Revenue Next Year
- ROOT $9.74
- SNDX $94.17
- P/E Ratio
- ROOT $20.12
- SNDX N/A
- Revenue Growth
- ROOT 59.76
- SNDX 2126.66
- 52 Week Low
- ROOT $36.87
- SNDX $8.58
- 52 Week High
- ROOT $181.14
- SNDX $22.50
- Technical
- Relative Strength Index (RSI)
- ROOT 52.45
- SNDX 50.61
- Support Level
- ROOT $94.78
- SNDX $14.67
- Resistance Level
- ROOT $102.47
- SNDX $16.50
- Average True Range (ATR)
- ROOT 4.61
- SNDX 0.78
- MACD
- ROOT 1.55
- SNDX -0.35
- Stochastic Oscillator
- ROOT 81.15
- SNDX 16.80
About ROOT Root Inc.
Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. It generates revenue from the sales of auto insurance policies within the United States.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.